Abstract
The systematic identification of infected individuals is critical for the containment of the COVID-19 pandemic. Presently, the spread of the disease is mostly quantified by the reported numbers of infections, hospitalizations, recoveries and deaths; these quantities inform epidemiology models that provide forecasts for the spread of the epidemic and guide policy making. The veracity of these forecasts depends on the discrepancy between the numbers of reported and unreported, yet infectious, individuals.
We combine Bayesian experimental design with an epidemiology model and propose a methodology for the optimal allocation of limited testing resources in space and time, which maximizes the information gain for such unreported infections. The proposed approach is applicable at the onset and spreading of the epidemic and can forewarn for a possible recurrence of the disease after relaxation of interventions. We examine its application in Switzerland; the open source software is, however, readily adaptable to countries around the world.
We find that following the proposed methodology can lead to vastly less uncertain predictions for the spread of the disease. Estimates of the effective reproduction number and of the future number of unreported infections are improved, which in turn can provide timely and systematic guidance for the effective identification of infectious individuals and for decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge funding by ETH Zurich and computing resources by the Swiss Supercomputing center (CSCS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable here.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The open source software is available on Github.
